» Articles » PMID: 29444987

Cardiovascular Risk Prediction Functions Underestimate Risk in HIV Infection

Overview
Journal Circulation
Date 2018 Feb 16
PMID 29444987
Citations 95
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cardiovascular disease (CVD) risk is elevated in HIV-infected individuals, with contributions from both traditional and nontraditional risk factors. The accuracy of established CVD risk prediction functions in HIV is uncertain. We sought to assess the performance of 3 established CVD risk prediction functions in a longitudinal cohort of HIV-infected men.

Methods: The FHS (Framingham Heart Study) functions for hard coronary heart disease (FHS CHD) and atherosclerotic CVD (FHS ASCVD) and the American College of Cardiology/American Heart Association ASCVD function were applied to the Partners HIV cohort. Risk scores were calculated between January 1, 2006, and December 31, 2008. Outcomes included CHD (myocardial infarction or coronary death) for the FHS CHD function and ASCVD (myocardial infarction, stroke, or coronary death) for the FHS ASCVD and American College of Cardiology/American Heart Association ASCVD functions. We investigated the accuracy of CVD risk prediction for each function when applied to the HIV cohort using comparison of Cox regression coefficients, discrimination, and calibration.

Results: The HIV cohort was comprised of 1272 men followed for a median of 4.4 years. There were 78 (6.1%) ASCVD events; the 5-year incidence rate was 16.4 per 1000 person-years. Discrimination was moderate to poor as indicated by the low statistic (0.68 for FHS CHD, 0.65 for American College of Cardiology/American Heart Association ASCVD, and 0.67 for FHS ASCVD). Observed CVD risk exceeded the predicted risk for each of the functions in most deciles of predicted risk. Calibration, or goodness of fit of the models, was consistently poor, with significant χ values for all functions. Recalibration did not significantly improve model fit.

Conclusions: Cardiovascular risk prediction functions developed for use in the general population are inaccurate in HIV infection and systematically underestimate risk in a cohort of HIV-infected men. Development of tailored CVD risk prediction functions incorporating traditional CVD risk factors and HIV-specific factors is likely to result in more accurate risk estimation to guide preventative CVD care.

Citing Articles

Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVE.

Grinspoon S, Zanni M, Triant V, Kantor A, Umbleja T, Diggs M Lancet HIV. 2025; 12(2):e118-e129.

PMID: 39832519 PMC: 11890582. DOI: 10.1016/S2352-3018(24)00276-5.


Evaluation of Cardiovascular Risk Profile and Risk Scores of Antiretroviral Therapy-naïve HIV Patients in Eastern India.

Chaubey M, Chakravarty J, Gupta R, Jethwani P, Puri R, Sundar S J Glob Infect Dis. 2024; 16(3):104-110.

PMID: 39619366 PMC: 11606546. DOI: 10.4103/jgid.jgid_29_24.


Optimizing cardiometabolic risk in people living with human immunodeficiency virus: A deep dive into an important risk enhancer.

Kobe E, Thakkar A, Matai S, Akkaya E, Pagidipati N, McGarrah R Am J Prev Cardiol. 2024; 20:100888.

PMID: 39552706 PMC: 11566711. DOI: 10.1016/j.ajpc.2024.100888.


Association between the triglyceride to high-density lipoprotein cholesterol ratio and cardiovascular diseases in people living with human immunodeficiency virus: Evidence from a retrospectively cohort study 2005-2022.

Sun L, Luo Y, Jia X, Wang H, Zhao F, Zhang L Chin Med J (Engl). 2024; 137(22):2712-2719.

PMID: 39450977 PMC: 11611243. DOI: 10.1097/CM9.0000000000003326.


Cardiovascular medication adherence testing in patients living with HIV: A single-centre observational study.

Nazareth J, Adebayo A, Fahad M, Karim H, Pan D, Sze S HIV Med. 2024; 25(12):1330-1339.

PMID: 39315489 PMC: 11608581. DOI: 10.1111/hiv.13715.


References
1.
Anderson K, Wilson P, Odell P, Kannel W . An updated coronary risk profile. A statement for health professionals. Circulation. 1991; 83(1):356-62. DOI: 10.1161/01.cir.83.1.356. View

2.
Lloyd-Jones D, Morris P, Ballantyne C, Birtcher K, Daly Jr D, DePalma S . 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical.... J Am Coll Cardiol. 2016; 68(1):92-125. DOI: 10.1016/j.jacc.2016.03.519. View

3.
Wolf P, DAgostino R, Belanger A, Kannel W . Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991; 22(3):312-8. DOI: 10.1161/01.str.22.3.312. View

4.
Freiberg M, Chang C, Kuller L, Skanderson M, Lowy E, Kraemer K . HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013; 173(8):614-22. PMC: 4766798. DOI: 10.1001/jamainternmed.2013.3728. View

5.
DAgostino Sr R, Grundy S, Sullivan L, Wilson P . Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001; 286(2):180-7. DOI: 10.1001/jama.286.2.180. View